Canada approves BioCurex' Histo-RECAF cancer diagnostic:
This article was originally published in Clinica
Executive Summary
Canada has approved for sale BioCurex' Histo-RECAF diagnostic test kit for detecting cancers of the breast, lung, stomach, prostate and lymph node tissues. The test, which can detect malignant cancers from blood or tissue samples, is based on the identification of a common cancer biomarker, known as RECAF. The Rancho Santa Margarita, California firm says that research has shown the test to have a sensitivity of 100% in the detection of breast cancer (see Clinica No 967, p 17). It adds that it will also file for approval in other strategic markets shortly.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.